We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Organoids Aid Discovery of New Approaches for Treating Pancreatic Cancer

By LabMedica International staff writers
Posted on 25 Jan 2015
Print article
Image: Researchers have developed a three-dimensional culture system to grow organoids from mouse and human pancreatic tissue. The technology promises to change the way pancreatic cancer research is done, offering a path to personalized treatment approaches (Photo courtesy of Cold Springs Harbor Laboratory).
Image: Researchers have developed a three-dimensional culture system to grow organoids from mouse and human pancreatic tissue. The technology promises to change the way pancreatic cancer research is done, offering a path to personalized treatment approaches (Photo courtesy of Cold Springs Harbor Laboratory).
Cancer researchers have established a method for culturing organoids from normal and cancerous mouse and human pancreatic tissues that is expected to boost development of personalized treatment approaches for this deadly disease.

Since pancreatic cancer is one of the most lethal malignancies due to its late diagnosis and limited response to treatment, methods to identify and study molecular pathways involved in tumor development are urgently needed. Towards this end investigators at Cold Spring Harbor Laboratory (NY, USA) established organoid models from normal and cancerous mouse and human pancreas tissues. Pancreatic organoids could be rapidly generated from resected tumors and biopsies, survive cryopreservation, and exhibit ductal- and disease-stage-specific characteristics. Normal ductal cells that are able to develop into pancreatic cancer represent only about 10% of the cells in the pancreas, but the organoids were entirely composed of ductal cells, which eliminated surrounding cell types that often contaminate pancreatic samples.

Details published in the December 2014 online edition of the journal Cell revealed that the organoids were grown as hollow spheres within a complex gel-like substance filled with growth-inducing factors and connecting fibers. Once they had grown to a sufficient size, the organoids were transplanted into mice, where they fully recapitulated all the stages of pancreatic cancer development from early-grade neoplasms that progressed to locally invasive and metastatic carcinomas.

Due to their ability to be manipulated genetically, organoids served as an ideal platform to probe genetic cooperation. Comprehensive transcriptional and proteomic analyses of mouse pancreatic organoids revealed genes and pathways altered during disease progression. The confirmation of many of these protein changes in human tissues demonstrated that organoids were a useful model system to discover characteristics of this deadly malignancy.

“With this development, we are now able to culture both mouse and human organoids, providing a very powerful tool in our fight against pancreatic cancer,” said senior author Dr. David Tuveson, professor of pancreatic cancer medicine at Cold Spring Harbor Laboratory. “We hope to make this available to the entire pancreatic cancer research community.”

Related Links:

Cold Spring Harbor Laboratory


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more